Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCPGlobeNewsWire • 01/10/23
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in SwitzerlandGlobeNewsWire • 12/07/22
Amarin Corporation plc (AMRN) Presents at 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)Seeking Alpha • 11/16/22
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in AustraliaGlobeNewsWire • 11/15/22
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient CareGlobeNewsWire • 11/07/22
Amarin Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 10/27/22
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022GlobeNewsWire • 10/20/22
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board MembersBusiness Wire • 10/11/22
Amarin Corporation Plc (AMRN) H.C. Wainwright Global Investment Conference Call TranscriptSeeking Alpha • 09/12/22
Amarin to Present at H.C. Wainwright's 24th Annual Global Investment ConferenceGlobeNewsWire • 08/30/22
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former SmokersGlobeNewsWire • 08/28/22
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI SubtypesGlobeNewsWire • 08/26/22